An overview of PROTACs: a promising drug discovery paradigm.
Liu Z, Hu M, Yang Y, Du C, Zhou H, Liu C, Chen Y, Fan L, Ma H, Gong Y, Xie Y. · 2022
Read An overview of PROTACs: a promising drug discovery paradigm. by Liu Z, Hu M, Yang Y, Du C, Zhou H, Liu C, Chen Y, Fan L, Ma H, Gong Y, Xie Y. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9763089.txt.
Description
Liu and co-authors give an overview of PROTACs as a fresh drug discovery approach. These molecules destroy target proteins instead of just blocking them. They hijack the cell's own protein shredding system to do it. A PROTAC has two gripping ends joined by a linker.
One end holds the target and the other holds a tagging enzyme. Brought together, the target gets marked for destruction. The whole protein vanishes, not just one active site. That opens targets long called undruggable to drug work. Scaffolding proteins and gene switches become reachable this way. Two such drugs showed strong results in mid stage trials. The review lays out design rules for the linkers and ends. It sorts uses by protein class, from kinases to receptors. Oral dosing and target choice remain open challenges. The authors weigh those limits against the gains.
Catalog record
| CREATOR | Liu Z, Hu M, Yang Y, Du C, Zhou H, Liu C, Chen Y, Fan L, Ma H, Gong Y, Xie Y. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 119 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |